Study of PMD-026 for worsening myelofibrosis
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia) that is in the chronic phase
- You have tried a JAK inhibitor (such as ruxolitinib) for at least 12 weeks, and it stopped working, caused side effects, or you couldn't tolerate it
- Your myelofibrosis is classified as intermediate-2 or high-risk (a measure of how advanced your disease is)
- You have an enlarged spleen (at least 450 cubic centimeters on imaging, or your doctor can feel it 5 centimeters below your ribs)
- You have at least 10 symptoms on a myelofibrosis symptom score (such as fatigue, night sweats, or itching)
- You are 18 years or older and have adequate organ function and blood counts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called revumenib, either alone or combined with a JAK inhibitor, for people with myelofibrosis that is still active despite standard treatment. The goal is to see if revumenib can better control symptoms, reduce spleen size, or improve blood counts.
This trial tests two oral medications, momelotinib and ruxolitinib, to see which works better for people with newly diagnosed myelofibrosis who also have low blood cell counts. You may be able to join if your spleen is enlarged and you haven't had prior treatment with certain drugs.
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
This trial tests a combination of two drugs, selinexor and pacritinib, for people with myelofibrosis who have not had previous JAK inhibitor treatment and have low red blood cells (anemia) or low platelets. The goal is to see if these drugs can help improve symptoms and reduce spleen size while being safe for patients with cytopenias.
This trial tests a new drug called RVU120 for people with myelofibrosis that has not responded well to standard JAK inhibitor treatment. It aims to shrink the spleen and improve symptoms.
This trial tests an oral drug called tasquinimod for people with myelofibrosis that no longer responds to or cannot take a JAK inhibitor. The goal is to see if tasquinimod can help shrink an enlarged spleen and improve symptoms.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.